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Abstract
Background: This study aimed to investigate the correlation of minimum inhibiting concentrations (MICs),
obtained by broth micro-dilution, and clinical response in patients with cryptococcal meningitis.
Methods: Using retrospective analyses covering the period 2001–2010, factors affecting clinical therapeutic cure in
patients with cryptococcal meningitis 10 weeks after the start of anti-fungal therapy were identified. Specific
emphasis was placed on the role of anti-fungal susceptibility.
Results: Of 46 patients with cryptococcal meningitis identified, 21 were cured after 10 weeks of treatment. Overall,
12 strains (26.1%) were resistant to fluconazole (>8 μg/ml) and 8 (17.4%) had an MIC >1 μg/ml for amphotericin B.
Twenty-three patients received combination amphotericin B and fluconazole as their initial antifungal therapy, 17
were given amphotericin B only, five received fluconazole only, and one received a combination of amphotericin B
and flucytosine. After 2 weeks, all patients received fluconazole (400–600 mg daily for 8 weeks at least, then 200
mg daily thereafter). The presence of isolates resistant to fluconazole (MIC >8 μg/ml; 4.8% vs. 44%, p < 0.01) were
statistically significant among patients who were cured. Anti-fungal susceptibility, reflected by fluconazole
MIC >8 μg/ml, was an independent predictor of therapeutic cure at 10-week evaluation (OR = 15.7;
95% CI: 1.8-135.9; p = 0.01), but higher MIC of amphotericin B (>1 μg/ml) was not.
Conclusions: The MICs of fluconazole, determined by the CLSI method, may be a potential predictor of therapeutic
cure in patients with cryptococcal meningitis.
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Background
Cryptococcus neoformans is an encapsulated yeast re-
sponsible for life-threatening infections, particularly in
immuno-compromised patients like those with AIDS
[1]. Pharmacologic management usually consists of pri-
mary therapy with amphotericin B, with or without flu-
cytosine, followed by maintenance therapy [2]. High
rates of fungal persistence and frequent relapse have
sparked growing concern among clinicians on the
possible emergence of anti-fungal resistance. There are
now several published reports of resistance to amphoter-
icin B, fluconazole, or flucytosine in C. neoformans dur-
ing treatment [3-6]. Most cases involve resistance to
fluconazole in the setting of meningitis in AIDS patients
after prolonged treatment or prophylaxis [4-6].
Physicians have long sought a laboratory test to pre-
dict clinical outcomes in patients with cryptococcosis.
The Clinical and Laboratory Standards Institute (CLSI)
recently established a reproducible method for testing
the susceptibility of C. neoformans to anti-fungal drugs
[7]. However, in vitro susceptibility testing methods (in-
cluding the CLSI method and breakpoints) for Crypto-
coccus species have not been well-validated [2]. One
report concludes that in vitro anti-fungal susceptibility
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does not predict clinical outcomes in patients with
cryptococcosis [8], whereas others report that high mini-
mum inhibiting concentrations (MICs) of fluconazole
affect outcomes [9,10]. Unfortunately, these studies are
confounded by selection bias because most of them en-
rolled AIDS patients and most C. neoformans isolates
are susceptible to fluconazole [8-10].
The present study investigated the correlation between
the MICs of amphotericin B or fluconazole (obtained by
the broth micro-dilution method described in the CLSI
document M27-A3) with the clinical responses of
cryptococcal meningitis patients, excluding those with
AIDS only. In the context of recent emerging non-
susceptible strains of C. neoformans, the objective was to
validate an in vitro measure that could reliably predict




Data covering the period January 2001 to December
2010 were retrospectively collected from patients with
cerebrospinal fluid (CSF) cultures positive for Cryptococ-
cus neoformans admitted to Kaohsiung Chang Gung Me-
morial Hospital (KCGMH), a 2300-bed facility serving as
a primary care and tertiary referral center in southern
Taiwan. If a patient had multiple positive results for C.
neoformans, only the first instance was included. Demo-
graphic and clinical information, including the anti-
fungal treatment used in each case, were obtained. The
Chang Gung Memorial Hospital’s Institutional Review
Board approved the study [No.99-1408C].
Data on clinical variables, including age, sex, under-
lying diseases (i.e., AIDS, steroids usage, diabetes melli-
tus, liver cirrhosis, malignancy, chronic renal failure,
chronic obstructive pulmonary disease, and organ trans-
plantation) and use of systemic anti-fungal therapy one
month prior to first positive cryptococcal CSF culture
were collected. Diabetes mellitus was defined as
hemoglobin A1c >7%, with random blood glucose level
>200 mg/dl or fasting blood glucose level > 126 mg/dl in
repeated tests during the hospital stay, or if the patient
had previously been diagnosed with diabetes mellitus.
The severity of illness at the time of CSF sampling was
assessed using a modified APACHE II scoring method
[11], and stratified based on the need for admission to
an intensive care unit (ICU). The APACHE II scoring
was modified as follows: zero points were given to the
items PaO2 and pH if arterial blood gas analysis was not
performed because of the absence of respiratory distress.
Increasing intra-cranial pressure (IICP) was defined as
an elevated opening pressure >200 mmH20. If there was
evidence of high intracranial pressure with obstruction
that needed decompression, drainage was done via
ventriculo-peritoneal shunt in accordance with IDSA
guidelines [12]. Laboratory data collected included lum-
bar puncture findings (opening pressure, India ink
smear, and CSF levels of cryptococcal antigen), initial
serum level of cryptococcal antigen, and results of blood
fungal cultures.
Forty-six patients with cryptococcal meningitis were
identified during the 10-year study period, including 32
men and 14 women, with age range between 18 and 85
years. Forty-two (91.3%) were tested for HIV and six
were infected.
Clinical evaluation
The 46 patients were divided into 4 groups based on
their initial anti-fungal treatment regimen used during
the first 2 weeks. Twenty-three patients received a com-
bination of amphotericin B and fluconazole as their ini-
tial anti-fungal therapy; 17 had amphotericin B only; 5
received fluconazole (400–800 mg daily) only; and 1
received a combination of amphotericin B and flucyto-
sine. After 2 weeks, patients in all groups received fluco-
nazole (400–600 mg daily for 8 weeks at least, then 200
mg daily thereafter). Follow-up was conducted after 2
weeks of treatment to assess the early outcomes of the
disease.
Due to the sub-acute nature of the infection, the pri-
mary outcome measure was the clinical outcome after
10 weeks of treatment. Therapeutic cure was defined as
improvement or disappearance of symptoms, negative
clinical findings (i.e., fever, meningitis, neurological dis-
order, and abnormal mental status) and sterile CSF cul-
ture at the time of evaluation. Therapeutic failure was
defined as either 1) clinical deterioration during
hospitalization, including progressive hydrocephalus
from comparison with initial cranial computed tomog-
raphy (CT) study; new onset CNS vasculitis demon-
strated by brain CT; seizure or status epilepticus with
progressive disturbed conscious state; and a modified
Barthel Index score <12 [13]; or 2) presence of C. neofor-
mans in the patient’s CSF at the time of evaluation.
Death resulting from any cause was recorded at the time
of evaluation.
Fungal strain
The processing of specimens and isolate identification
were performed by conventional methods and with the
YBC identification card (bioMerieux, Marcy l’Etoile,
France). The isolated strains were preserved at −70°C
until the experiments.
Isolation of genomic DNA and PCR amplification
Each strain was grown on SDA plates at 35°C for 2 days.
Cells were collected and suspended in a TE buffer (100
mM Tris–HCl; pH 8.0, 1 mM EDTA) containing lyticase
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(Sigma, St. Louis, MO, USA). Glass beads (Sigma) were
then added to the micro-tubes, and the samples were
incubated at 37°C for 4 h, and mixed in an end-over-end
mixer to digest cell walls. Genomic DNA was extracted
from the cells with the High Pure PCR template prepar-
ation kit (Roche Applied Science, Mannheim, Germany)
according to the manufacturer’s instructions.
The serotype of Cryptococcus neoformans was identi-
fied by multiplex PCR [14]. Briefly, four primers for
cloning LAC116 and 2 for CAP64 were used. The ampli-
fied products were electrophoretically separated and
stained with ethidium bromide. The DNA bands were
extracted using a gel extraction kit (QIAquick, QIAGEN
Sciences, Germantown, MD, USA) and sequenced dir-
ectly using a BigDye Terminator Cycle-sequencing kit
(ABI PRISM 310NT Genomic Analyzer, Perkin-Elmer
Applied Biosystems, Foster, CA, USA).
Anti-fungal susceptibility testing
Anti-fungal susceptibilities were determined using the
broth micro-dilution method according to the CLSI
M27-A3 methodology [7]. The anti-fungal agents tested
were fluconazole (Pfizer, New York, NY, USA), voricona-
zole (Pfizer), and amphotericin B deoxycholate (Sigma).
Stock solutions were prepared in dimethyl sulfoxide
(voriconazole and amphotericin B) or water (flucona-
zole), and were further diluted in RPMI 1640 medium
(Sigma) buffered to a pH level of 7 with 0.165 M 3-(N-
morpholino) propanesulfonic acid buffer (Sigma). Ali-
quots of each agent (0.1 ml) at 2× concentrations were
dispensed into 96-well micro-dilution trays. Inocula con-
taining 0.5 × 103 to 2.5 × 103 cells/ml were then added to
each well and the trays were incubated at 35°C. The final
anti-fungal concentrations ranged from 0.06 to 8 μg/ml
for voriconazole and amphotericin B, and from 0.25 to
64 μg/ml for fluconazole.
The MICs for voriconazole and fluconazole were read
as concentrations causing a 50% reduction in turbidity
compared to the growth of the control at 72 h. For
amphotericin B, the MICs were read as the concentra-
tions resulting in 100% inhibition relative to that of the
growth of controls. Candida krusei ATCC 6258 and
Candida parapsilosis ATCC 22019 were used as quality
controls. The interpretative criteria for susceptibility to
fluconazole was as published by the CLSI as ≤8 μg/ml
[7]. Because there were no established interpretative cri-
teria for amphotericin B and voriconazole, isolates with
MICs that were both ≤1 μg/ml were considered suscep-
tible, as suggested by Nguyen and Yu [15] and Lozano-
Chiu et al. [16].
Statistical analysis
Statistical analysis was conducted using the SPSS statis-
tical analysis system. If 2 or more C. neoformans strains
were isolated from a patient, the first isolated strain was
included in the analysis. When C. neoformans was iso-
lated from a patient’s blood and CSF, the isolate from
the CSF specimen was included in the analysis. Forty-six
C. neoformans isolates were analyzed. In the univariate
analysis, a comparison of contingency data was per-
formed using the Chi-squared test or Fisher’s exact test,
as appropriate. Factors with p < 0.1 in univariate analyses
were separately entered into a multiple logistic regres-
sion model to identify independent predictive factors for
the successful cure of cryptococcal meningitis at the
time of evaluation. Variables with a two-tailed p < 0.05
were considered statistically significant.
Results
The serotype of C. neoformans was serotype A in 41 iso-
lates and serotype B in 5 isolates. The susceptibilities of
the 46 strains to fluconazole, amphotericin B, and vori-
conazole were determined by CLSI (Table 1). The widest
ranges and highest MICs were for fluconazole (2–32 μg/
ml), whereas the lowest MIC was for voriconazole (≤0.5
μg/ml). Overall, 12 strains (26.1%) were not susceptible
to fluconazole (>8 μg/ml) and 8 (17.4%) had an MIC >1
μg/ml for amphotericin B.
Fifteen patients exhibited worsening symptoms of
cryptococcal meningitis and five died from cryptococcal
infection on or before the end of the 2-week therapy.
Compared to the 20 patients who were not cured, the 26
patients who were cured after 2 weeks of initial therapy
showed some statistically significant characteristics, in-
cluding age <60 years (76.9% of cured patients versus
45% of uncured patients were younger than 60 years;
p = 0.04). There was no relationship between anti-
fungal susceptibility or induction treatment modality and
therapeutic cure at the two-week interim analysis (Table 2).
Multivariate logistic regression analysis indicated that
Table 1 Inhibitory activities of amphotericin B, fluconazole, and voriconazole against clinical isolates of Cryptococcus
neoformans (n = 46) from initial cerebro-spinal fluid culture
Anti-fungal agent Cumulative % inhibited at MIC (μg/ml)
0.06 0.12 0.25 0.5 1 2 4 8 16 32
Amphotericin B 0 0 6.5 36.9 82.6 100
Fluconazole 0 0 0 8.7 28.3 74 95.7 100
Voriconazole 8.7 52.2 91.3 100
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Table 2 Demographic characteristics, laboratory results, and treatment modalities of patients with cryptococcal
meningitis (n = 46) at two-week evaluation
Variables Cured (%) (n = 26) Not cured# (%) (n = 20) p value
Demographics
Male sex 19 (73.1) 13 (65) 0.75
Age >60 years 6 (23.1) 11 (55) 0.04
Coexisting conditions
AIDS 2 (8.3)a 4 (22.2)b 0.38
Solid tumor malignancy 2 (7.7) 4 (20) 0.38
Hematologic malignancy 3 (11.5) 1 (5) 0.62
Steroid usage 3 (11.5) 5 (25) 0.27
Liver cirrhosis 1 (3.8) 4 (20) 0.37
Chronic renal failure 2 (7.6) 1 (5) 1
Diabetic mellitus 8 (30.8) 4 (20) 0.51
COPD 4 (15.4) 0 0.12
Organ transplantation 1 (3.8) 0 1
No known predisposing factorc 6 (23.1) 2 (10) 0.44
Previous anti-fungal therapyd 3 (11.5) 4 (20) 0.68
Severity status
APACHE-II score 8.2 ± 2.4 10.4 ± 3.7 0.19
APACHE-II score≥ 15 5 (19.2) 5 (25) 0.73
Shock 1 (3.8) 0 1
IICP 23 (88.5) 18 (90) 1
ICU admission 14 (53.8) 8 (40) 0.39
Initial laboratory data
India ink smear positive 12 (46.2) 11 (55) 0.77
CSF opening pressure (mmH20) 248 ± 132 252 ± 136 0.58
CSF WBC count (/μL) 32.2 ± 40.6 28.8 ± 38.6 0.28
CSF CAT≥ 1:1024 13 (50) 14 (70) 0.23
Serum CAT≥ 1:1024 9 (34.6) 9 (45) 0.55
Concurrent cryptococcemia 6 (23.1) 6 (30) 0.74
Serotype B Cryptococcus neoformans isolate 4 (15.4) 1 (5) 0.37
Isolate resistant to fluconazole (MIC >8 μg/ml) 4 (15.4) 8 (40) 0.09
Isolate resistant to amphotericin B (MIC >1 μg/ml) 3 (11.5) 5 (25) 0.27
Treatment modality in induction therapy
Amphotericin B plus flucytosine 0 1 (5) 0.44
Amphotericin B plus fluconazole 10 (38.5) 13 (65) 0.14
Amphotericin B alone 12 (46.2) 5 (25) 0.22
Fluconazole alone 4 (15.4) 1 (5) 0.37
Abbreviations: AIDS acquired immuno-deficiency syndrome, CAT cryptococcal-antigen titer, COPD chronic obstructive pulmonary disease, CSF cerebro-spinal fluid,
ICU intensive care unit, IICP increasing intra-cranial pressure.
# Non-cured patients included 15 patients who failed to respond to cryptococcal meningitis treatment by the end of two weeks of initial anti-fungal therapy, and
five who died from cryptococcal infection before the end of two weeks of initial anti-fungal therapy.
aNumber of patients available for analysis, n = 24.
bNumber of patients available for analysis, n = 18.
cAll 8 patients without known predisposing factor were tested for HIV and none was infected.
dReceived systemic anti-fungal agents one month prior to first positive cryptococcal cerebro-spinal fluid culture.
*Multivariate logistic regression analysis indicated that age >60 years (OR = 4.1; 95% CI: 1.1-14.5; p = 0.03) was an independent predictive factor for poor clinical
outcome (failure and death) of cryptococcal meningitis at 2-week evaluation.
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patient age >60 years (OR = 4.1; 95% CI: 1.1-14.5; p =
0.03) was an independent predictive factor for poor clin-
ical outcome (failure and death) of cryptococcal meningi-
tis at the two-week interim evaluation.
Seventeen patients exhibited worsening symptoms of
cryptococcal meningitis, and 8 died from cryptococcal
infection on or before the end of the 10-week therapy.
Compared to the 25 patients who were not cured, the 21
patients who were cured after 10 weeks of initial therapy
showed the presence of isolates resistant to fluconazole
(MIC >8 μg/ml) was significantly associated with non-
cure (4.8% of cured patients versus 44% of uncured
patients had resistant isolates; p < 0.01) (Table 3). There
was no relationship between initial induction treatment
modality and therapeutic cure at the 10-week evaluation.
Multivariate logistic regression analysis indicated that
the presence of isolates resistant to fluconazole (OR =
15.7; 95% CI: 1.8-135.9; p = 0.01) was an independent
predictive factor of poor clinical outcome (failure and
death) of cryptococcal meningitis at the 10-week
evaluation.
Clinical outcomes, initial induction treatment modal-
ity, and their relation to the susceptibility of amphoteri-
cin B and fluconazole were shown in Table 4. Among 12
C. neoformans isolates with high fluconazole MIC (>8
μg/ml), one patient received combined amphotericin B
and flucytosine therapy in the first 2 weeks, but died be-
fore the 10-week evaluation. Seven patients received
combined amphotericin B and fluconazole therapy in
the first 2 weeks, of which only one was cured, five failed
to respond, and one died. Three patients who received
amphotericin B therapy only in the first 2 weeks all
failed to respond. One patient who received fluconazole
therapy alone in the first 2 weeks died at the 10-week
evaluation. For eight isolates with high amphotericin B
MICs (>1 μg/ml), five patients received combined
amphotericin B and fluconazole therapy in the first 2
weeks, but only one was cured and 4 failed to respond
at the 10-week evaluation. Two patients received
amphotericin B therapy only in the first 2 weeks, and
both died before the 10-week evaluation. One patient
received fluconazole alone in the first 2 weeks and was
cured. For susceptibility to fluconazole, there was a
trend for resistance (MIC >8 μg/ml) to be associated
with poor clinical outcome (failure and death), irrespect-
ive of initial treatment modality, at the 10-week
evaluation.
Discussion
Cryptococcal meningitis is described as an opportunistic
infection in immuno-compromised patients such as
people infected with HIV, but it can also affect appar-
ently healthy people [17]. In the present study, only
6 (13%) of the 46 patients identified with cryptococcal
meningitis were documented as having AIDS. Sun et al.
[18] reported a mortality rate of 20.7% for HIV-infected
patients within 10 weeks of hospitalization with crypto-
coccosis. Similarly, the overall mortality rate in the
present study after 10 weeks of initial anti-fungal therapy
for cryptococcal meningitis was 17.4% (8 patients died).
The similarity in the mortality rates of these two studies
suggests that mortality rates caused by cryptococcal
meningitis may not be different for HIV-positive and
HIV-negative patients.
Factors predictive of poor prognosis and mortality in
patients with cryptococcal meningitis include (i) crypto-
coccus growth from sites other than CSF; (ii) alteration
in mental status; (iii) IICP; (iv) CSF glucose <40 mg/dL;
(v) CSF cell count <20 cells/mm3; (vi) high CSF crypto-
coccal antigen titer [19]; and (vii) positive India ink
smear [20]. The goal of treatment includes both cure of
the infection and prevention of long-term CNS system
sequelae [2]. Prognostic factors for mortality may be
overlooked because death may not be attributed to
cryptococcosis itself. Therefore, cure of the infection is
the endpoint of outcome evaluation in the current study.
High CSF cryptococcal antigen titer and the isolation
of cryptococci from extra-neural sites indicate increased
fungal load in patients with cryptococcal meningitis [21].
Although these clinical characteristics do not affect the
clinical outcomes used to determine therapeutic cure in
the current study, there is a consistent trend wherein
patients who failed were more likely to have co-
morbidities and that severity of illness that would pre-
dispose them to a poorer clinical outcome. The cured
patients were younger at 2-week interim analysis
(Table 2). Other negative results in this study may have
been due to low statistical power, rather than a true lack
of association between the clinical characteristic and
therapeutic cure.
Differing approaches exist for the in vitro measure-
ment of C. neoformans susceptibility to anti-fungal
agents. Anaissie et al. [22] evaluated YNB, RPMI 1640
medium broth, and Eagle’s minimum essential medium
broth, and found that RPMI 1640 broth was a suitable
medium to test the susceptibility of C. neoformans. Fran-
zot and Hamdan [23] corroborated these findings. RPMI
1640 medium is the standard broth recommended by
CLSI [7]. When using this medium, MIC determinations
require 72 h of incubation. Accordingly, the current
study evaluated in vitro activities of C. neoformans by
the broth micro-dilution method, as described in the
CLSI document M27-A3 [7].
For in vitro anti-fungal susceptibility testing of C. neo-
formans [7], no breakpoint is currently available for any
drug [2] and the role of the susceptibility of the initial
isolate as a predictor of both early and late clinical treat-
ment failure remains controversial [8-10]. One study
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Table 3 Demographic characteristics, laboratory results, and initial treatment modalities of patients with cryptococcal
meningitis (n = 46) at 10-week evaluation
Variables Cured (%) (n = 21) Not cured# (%) (n = 25) p-value
Demographics
Male sex 15 (71.4) 17 (68) 1
Age >60 years 6 (28.6) 11 (44) 0.36
Co-existing conditions
AIDS 1 (5.3)a 5 (21.7)b 0.19
Solid tumor malignancy 2 (9.5) 4 (16) 0.67
Hematologic malignancy 3 (14.3) 1 (4) 0.32
Steroid usage 2 (9.5) 6 (24) 0.26
Liver cirrhosis 1 (4.8) 4 (16) 0.36
Chronic renal failure 1 (4.8) 2 (8) 1
Diabetic mellitus 7 (33.3) 5 (20) 0.34
COPD 3 (14.3) 1 (4) 0.32
Organ transplantation 1 (4.8) 0 0.46
No known predisposing factorc 5 (23.8) 3 (12) 0.44
Previous anti-fungal therapyd 2 (9.5) 5 (20) 0.43
Severity status
APACHE-II score 7.2 ±3.4 10 ± 2.2 0.39
APACHE-II score≥ 15 4 (19.1) 6 (24) 0.74
Shock 1 (4.8) 0 0.46
IICP 19 (90.5) 22 (88) 1
ICU admission 12 (57.1) 10 (40) 0.38
Initial laboratory data
India ink smear positive 9 (42.9) 14 (56) 0.55
CSF opening pressure (mmH20) 254 ± 116 246 ± 122 0.68
CSF WBC count (/μL) 30.4 ± 42.8 28.6 ± 32.4 0.26
CSF CAT≥ 1:1024 11 (52.4) 16 (64) 0.55
Serum CAT≥ 1:1024 8 (38.1) 10 (40) 1
Concurrent cryptococcemia 4 (19.1) 8 (32) 0.50
Serotype B Cryptococcus neoformans isolate 4 (19.1) 1 (4) 0.16
Isolate resistant to fluconazole (MIC >8 μg/ml) 1 (4.8) 11 (44) <0.01*
Isolate resistant to amphotericin B (MIC >1 μg/ml) 2 (9.5) 6 (24) 0.26
Treatment modality in induction therapy
Amphotericin B plus flucytosine 0 1 (4) 1
Amphotericin B plus fluconazole 7 (33.3) 16 (64) 0.08
Amphotericin B alone 11 (52.4) 6 (24) 0.07
Fluconazole alone 3 (14.3) 2 (8) 0.65
Abbreviations: AIDS acquired immuno-deficiency syndrome, CAT cryptococcal-antigen titer, COPD chronic obstructive pulmonary disease, CSF cerebro-spinal fluid,
ICU intensive care unit, IICP increasing intra-cranial pressure.
#Non-cured patients included 17 patients who failed to respond to cryptococcal meningitis treatment by the end of 10 weeks of anti-fungal therapy and eight
who died from cryptococcal infection before the end of 10-week anti-fungal therapy.
aNumber of patients available for analysis, n = 19.
bNumber of patients available for analysis, n = 23.
cAll 8 patients without known predisposing factor were tested for HIV and none was infected.
dReceived systemic antifungal agents one month prior to first positive cryptococcal cerebro-spinal fluid culture.
*Multivariate logistic regression analysis indicated that the presence of Cryptococcus neoformans isolates resistant to fluconazole (OR = 15.7; 95% CI: 1.8-135.9;
p = 0.01) was an independent predictive factor for poor clinical outcome (failure and death) of cryptococcal meningitis at 10-week evaluation.
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with a sample of 74 patients with cryptococcosis (60 of
whom had AIDS) found that in vitro anti-fungal suscep-
tibility cannot predict the outcome two weeks after the
start of anti-fungal therapy [8]. However, the fluconazole
MICs of these isolates, which include C. neoformans
strains, are all ≤4 μg/ml [8]. Witt et al. explored the util-
ity of MICs as predictors of 2-week treatment failure in
patients receiving fluconazole for acute AIDS-associated
cryptococcal meningitis, and found that the low MIC of
fluconazole was independently associated with successful
treatment [9]. Aller et al. also reported that the clinical
outcomes of 25 patients (24 with AIDS) after 10 weeks
of fluconazole maintenance therapy might be better
when the infecting C. neoformans strain was inhibited by
lower concentrations of fluconazole for eradication
(MICs ≤8 μg/ml) than when patients were infected with
strains that required higher fluconazole concentrations
(MICs >8 μg/ml) [10]. These two studies both report
reduced treatment efficacies when the fluconazole MIC
is >8 μg/ml [9,10].
As in the present study, the MIC of fluconazole is
associated with early clinical outcome due to the very
few patients who receive fluconazole alone as induction
therapy. The use of combined therapy makes this prob-
lematic. Rather than focusing on early outcome, it may
make more sense to focus on the 10-week outcome
when the patients receive fluconazole as maintenance
therapy.
In the present study, only 13% patients had AIDS and
strains with higher fluconazole MICs (>8 μg/ml) were
specifically investigated. Despite using different testing
parameters, an association between high fluconazole
MICs (>8 μg/ml) and lack of therapeutic cure is evident.
One explanation is that strains with high MIC for fluco-
nazole (≥32 μg/ml) are more virulent than strains that
have low MIC for fluconazole (≤8 μg/ml) [24]. To date,
two studies has demonstrated a strong correlation be-
tween quantitative measures of in vitro amphotericin B
susceptibility and the quantitative response observed in
patients [25,26]. In the current study, the discrepancies
in susceptibilities to amphotericin B or fluconazole, and
clinical outcomes may be due to the small number of
patients infected by strains with high MICs of amphoter-
icin B. Further investigation is necessary on the correl-
ation between amphotericin B susceptibility and
outcomes in patients with cryptococcosis.
In a previous study, C. neoformans were collected from
the CSF specimens of patients with cryptococcal menin-
gitis between 1998 and 2002 [27]. By comparison, the
current study found that the MIC90 of fluconazole had
increased from 4 μg/ml [27] to 16 μg/ml for the CSF
specimens collected between 2001 and 2010 (Table 1).
Non-susceptibility to fluconazole was also an emerging
problem, according to surveillance data. This is espe-
cially true in certain global regions, notably Africa,
where prophylactic fluconazole is prescribed widely and
the drug is often used alone as the primary therapy for
cryptococcosis [4-6]. Initial treatment modality was not
associated with clinical outcome in either univariate or
multivariate analysis. Only one patient infected by
strains with higher fluconazole MICs (>8 μg/ml)
received fluconazole therapy alone in the first 2 weeks,
and this patient died before the end of the 2-week evalu-
ation. Only two patients infected by strains with higher
amphotericin B MICs (>1 μg/ml) received amphotericin
B therapy alone in the first 2 weeks, and both died be-
fore the end of the 2-week evaluation. Thus, early mor-
tality (first 2 weeks) from cryptococcal meningitis is
more likely elated to severity of disease at presentation
than treatment response.
Table 4 Susceptibility testing results (CLSI method) for
Cryptococcus neoformans isolates from patients, with













Cure 7 1 1










Abbreviations: 5FC flucytosine, AMB amphotericin B, FCZ fluconazole.
aThe 46 patients were divided into 4 groups based on their initial anti-fungal
treatment regimen used during the first 2 weeks. Thereafter, all patients
received fluconazole (400–600 mg daily for 8 weeks at least then 200 mg
daily).
bTherapeutic cure was defined as improvement or disappearance of
symptoms, negative clinical findings and the cerebro-spinal fluid culture was
sterile after 10 weeks of anti-fungal therapy. Therapeutic failure was associated
with the persistence of symptoms or cerebro-spinal fluid culture still yielding
C. neoformans after 10 weeks of anti-fungal therapy. Death was due to any
cause before the end of 10 weeks of anti-fungal therapy.
cThe interpretative criteria for susceptibility to fluconazole were those
published by the CLSI [7]. The criteria for susceptibility to amphotericin B were
those proposed by Nguyen and Yu [15].
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Moreover, 12 patients infected by strains with higher
fluconazole MICs (> 8 μg/ml) received fluconazole treat-
ment after 2 weeks initial antifungal therapy, and only
one was cured at the end of the 10-week evaluation.
This suggests that high fluconazole MIC is associated
with 10-week treatment failure when fluconazole is used
for maintenance therapy after induction therapy.
This study was subject to certain limitations. First, the
sample size was relatively small and made retrospective
use of patients’ medical records, which usually meant
that some data were missing or misclassified. Thus, the
findings may underestimate the “true” independent pre-
dictor of outcome in this study. Furthermore, the num-
bers of variables considered for the multiple logistic
regression analysis was small. Based on the stepwise pro-
cedures, only one variable was selected as the important
variable predicting the outcomes. The maximum likeli-
hood estimates of the coefficients are valid in the ana-
lysis. Not all the patients were checked for HIV because
two patients died before they could be screened for HIV
and another two patients did not accept HIV screening.
Second, flucytosine was unavailable at the study institu-
tion during the 10-year study period and only one pa-
tient received the most rapidly fungicidal regimen
(amphotericin B plus flucytosine) [28]. Third, the start of
induction anti-fungal therapy was different for each pa-
tient according to the preference of his/her doctor,
which might cause potential bias in statistical analysis.
Lastly, no standardization was conducted for certain
aspects of data collection, such as amphotericin B or flu-
conazole levels in serum and CSF. This limits the ability
to delineate the relationship between drug dosage, result-
ing serum and CSF levels, and treatment outcomes.
Conclusions
The present study suggests that primary non-susceptibility
to amphotericin B and fluconazole is common. The
MICs determined at the time of diagnosis of cryptococcal
meningitis by the CLSI M27-A3 broth micro-dilution
method may potentially predict the likelihood of thera-
peutic cure. Further large-scale studies are required to
corroborate the findings.
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